Table 1.
Characteristics of scFPM-guided patients
| Characteristics | Count | % |
|---|---|---|
| All | 56 | 100 |
| Sex | ||
| Male | 35 | 63 |
| Female | 21 | 37 |
| Age, median (range), y | 64 (23–86) | |
| Disease group | ||
| Lymphoma | 38 | 68 |
| Leukemia | 18 | 32 |
| B-NHL | 22 | 39 |
| AML | 14 | 25 |
| T-NHL | 15 | 27 |
| ALL/LBL | 5 | 9 |
| Number of previous treatments, median (range) | 3 (1–8) | |
| Response—last treatment | ||
| CR | 15 | 27 |
| PR | 12 | 21 |
| SD | 6 | 11 |
| PD | 23 | 41 |
| Sampling—treatment in days (range) | 21 (4–77) | |
| ECOG at treatment start | ||
| ECOG 0 | 17 | 30 |
| ECOG 1 | 22 | 39 |
| ECOG 2 | 11 | 12 |
| ECOG 3 | 6 | 11 |
| Sample blast fraction | ||
| High (>50%) | 34 | 61 |
| Medium (10%–50%) | 13 | 23 |
| Low (<10%) | 8 | 14 |
| NA | 1 | 2 |
Abbreviation: ALL, acute lymphoblastic leukemia; LBL, lymphoblastic lymphoma; NA, information not available; PD, progressive disease; SD, stable disease.